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Diffuse intrinsic pontine glioma (DIPG) is a highly aggressive pediatric brainstem tumor 
with a peak incidence in middle childhood and a median survival of less than 1 year. 
The dismal prognosis associated with DIPG has been exacerbated by the failure of 
over 250 clinical trials to meaningfully improve survival compared with radiotherapy, the 
current standard of care. The traditional practice to not biopsy DIPG led to a scarcity 
in available tissue samples for laboratory analysis that till recently hindered therapeutic 
advances. Over the past few years, the acquisition of patient derived tumor samples 
through biopsy and autopsy protocols has led to distinct breakthroughs in the iden-
tification of key oncogenic drivers implicated in DIPG development. Aberrations have 
been discovered in critical genetic drivers including histone H3, ACVR1, TP53, PDGFRA, 
and Myc. Mutations, previously not identified in other malignancies, highlight DIPG as 
a distinct biological entity. Identification of novel markers has already greatly influenced 
the direction of preclinical investigations and offers the exciting possibility of establishing 
biologically targeted therapies. This review will outline the current knowledge of the 
genomic landscape related to DIPG, overview preclinical investigations, and reflect how 
biological advances have influenced the focus of clinical trials toward targeted therapies.
Keywords: diffuse intrinsic pontine glioma, pediatric brainstem gliomas, histone H3K27M, ACvR1, PDGFR, 
preclinical studies, targeted therapies
inTRODUCTiOn
Diffuse intrinsic pontine glioma (DIPG) is a pediatric brainstem glioma that originates in the ventral 
pons, accounts for 75–80% of brainstem tumors in children and has a peak incidence in middle 
childhood (1–3). Histopathologically, DIPG have been classified as grade II–IV gliomas, namely, 
diffuse astrocytoma, anaplastic astrocytoma, or glioblastoma (GBM) (4). Under new recently defined 
WHO classification most would now be defined as diffuse midline gliomas with histone H3K27M 
mutation, as described below. Patients typically present with a neurological triad of cranial nerve 
deficits, ataxia, and long tract signs that have manifested over a short clinical history of less than 
3 months (1, 5). Diagnosis is ascertained from clinical signs accompanied by the presence of char-
acteristic radiological appearances (3, 5).
Due to the anatomical location of the tumor within the brainstem, they are unable to be resected, 
and in many centers are not biopsied. Palliative radiotherapy remains the sole standard therapy 
offered to patients albeit providing only transient improvements to neurological and radiological 
function (1, 5, 6). Chemotherapy as a neoadjuvant (7), combination (8–15), adjuvant (8–12, 14), and 
radiosensitizing (15, 16) agent has been extensively explored in over 250 clinical trials. Disappointedly, 
none of these studies have produced benefit meaningfully superior to radiotherapy, with the median 
TAble 1 | Major genomic mutations identified in diffuse intrinsic pontine 
glioma.
Mutation incidence 
(%)
Functional consequence Clinical outcome
Main drivers
1. Histone H3 80 The hypomethylation of 
histone H3 proteins, initiated 
by the conversion of a 
lysine to methionine residue, 
produces aberrant cell-
cycle function that initiates 
oncogenesis
•	 ↓ outcome vs. 
non-histone 
mutated tumors
H3.3 
(H3F3A)
60–71 •	 Median 
OS = 9 months
•	 ↓ response to 
radiotherapy
•	 ↑ metastasis
H3.1 
(HIST1H3B)
12–18 •	 Median 
OS = 15 months
•	 ↑ response to 
radiotherapy
•	 ↓ metastasis
2. ACVR1 20–32 Activation of the BMP 
pathway through the 
clustering of mutated 
residues at the glycine/serine 
enhanced domain
•	 Co-segregate 
with histone H3.1 
mutations
•	 ↑ median OS
3. TP53 22–40 Mutated TP53 in the setting 
of histone H3.3 allows for the 
evasion of cell death
•	 Co-segregate 
with histone H3.3 
mutations
•	 ↑ metastasis
4. PDGFRA 32 Phosphorylation of tyrosine 
kinase receptors triggers 
downstream activation of the 
PI3K and MAPK pathways
•	 Co-segregate 
with histone H3.3 
mutations
•	 Enriched proneural 
expression
•	 Clinically 
aggressive
Accessory drivers
5. PIK3R1/
PIK3CA
15 Oncogenes within the PI3K 
pathway are an obligate 
partner of histone H3.3 
present in clonal populations
•	 ↑ angiogenesis
•	 ↑ stem cell 
formation
2
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OS ranging from 9 to 12 months (8, 12, 13, 16) and 1-year survival 
rates of 27–61% (12, 14, 16). The role of MRI in diagnosis, in 
addition to the concern that tissue biopsy may lead to increased 
morbidity, has till recently meant that tissue samples have rarely 
been available for preclinical research, thus hampering biologi-
cally driven therapeutic advances (3).
The recent establishment of stereotactic biopsy and autopsy 
protocols has allowed for acquisition of primary tumor samples 
that have subsequently facilitated extensive genomic profil-
ing and crucial breakthroughs in key oncogenic drivers (17). 
Understanding the mutational processes underlying DIPG is of 
vital importance to identifying critical oncogenic pathways and 
defining high-frequency mutations with potential therapeutic 
relevance (18). The identification of biological markers with estab-
lished targeted agents has transformed the design and direction 
being undertaken in preclinical and clinical trials with encourag-
ing results already being discovered (19–21). This review will 
highlight the current state of knowledge of DIPG tumor biology 
and underlying genomic processes. It will subsequently outline 
how this understanding is beginning to guide research in both 
preclinical models and in clinical trials of novel targeted agents.
THe GenOMiC lAnDSCAPe OF DiPG
Describing the genomic landscape underpinning DIPG tumo-
rigenesis is vital to characterizing key oncogenic pathways and 
high-frequency mutations that represent actionable targets (18, 
22). Pathway analysis of protein and mRNA profiles suggests that 
DIPG is a unique type of glioma while sharing some biological 
similarities with supratentorial high-grade gliomas (HGG) such as 
GBM (18, 23). Despite the highly malignant nature of DIPG, only 
a limited number of somatic mutations are yet to be implicated as 
disease defining. The identification of mutations such as histone 
H3, ACVR1, TP53, PDGFRA, PIK3CA, and MYC highlight, 
important somatic events associated with tumor evolution (18, 
24, 25) (Table 1). However, intra- and inter-tumor heterogeneity 
has been observed within these disease-defining markers thereby 
reflecting the inherent barriers toward engendering effective 
therapeutic strategies (24). Additional somatic aberrations impli-
cated in DIPG include gains in chromosomes 1q (H3F3A), 2q, 8q, 
and 9q, as well as repeated losses of chromosomes 11p, 17p13.1, 
14q, 18p, and 22q (26–29). The discovery of histone mutations, 
present in up to 80% of DIPG tumors, has revolutionized our 
understanding of DIPG biology and introduces the potential for 
redefining clinical and therapeutic management (23, 30, 31). The 
histone mutation H3K27M is caused by the conversion of a lysine 
to methionine at residue 27, inducing unique gain-of-function 
mechanisms that lead to the loss of histone trimethylation 
(H3K27me3). Reduced H3K27me3 inhibits polycomb repressive 
complex 2 and promotes abnormal epigenetic silencing (26, 30). 
Functional analysis has highlighted the role of H3K27M as con-
tributing to abnormal cell-cycle control, inhibition of autophagy 
and potentially augmenting tumor resistance to radiotherapy 
(23). However, the precise role of H3K27M in tumor initiation 
remains undefined as it is not sufficient on its own for tumori-
genesis in vivo (32). However, the combination of H3K27M with 
additional mutational events, such as altered cell-cycle regulatory 
genes (TP53/PPM1D) and growth factor related pathways 
(ACVR1/PI3KR1), synergistically enhances tumorigenesis and 
together is thought to be early transformational event in DIPG 
(26, 32, 33). In vitro and in  vivo models of developmentally 
relevant neural stem cells with combined histone H3.3, p53, 
and PDGFR mutations demonstrate increased tumor formation 
compared to non-mutated counterparts (32).
Histone mutations are subclassified into H3.1 or H3.3 vari-
ants, encoded by the HIST1H3B and H3F3A genes, respectively, 
and include additional novel mutants in HIST2H3C and a lysine 
to isoleucine substitution (26, 30). H3.1 K27M mutations are 
exclusively linked to DIPG whereas H3.3 mutations in K27M 
and G34R/V (a glycine substitution of arginine or valine at 
position 34) are implicated in midline and supratentorial lateral 
tumors GBM, respectively (26, 34). The clinicopathological vari-
ation existing between the H3.1 and H3.3 subgroups, including 
differing median OS, phenotype, and responses to radiation, 
reflects previously unrecognized links between DIPG biology 
and clinical outcome (26, 31). Histone H3.1 is associated with a 
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slight improved survival benefit with a median OS of 15 months 
and reduced presence of metastasis, whereas histone H3.3 has 
a median OS of 9 months and an inferior response to radiation 
therapy (17). Overall, tumors containing the presence of any H3 
mutation are associated with poorer outcomes compared with 
non-histone mutated tumors (19, 26).
ACVR1 mutations have been identified in up to 32% of 
DIPG tumors, co-segregate with H3.1 mutations, and have been 
linked to increased median OS (18, 35, 36). Mutated residues 
cluster around the inhibitory glycine/serine enhanced domain or 
ATP-binding region and shift the kinase into an active conforma-
tion, subsequently leading to BMP pathway activation (18, 35). 
Somatic mutations in ACVR1 are almost exclusively limited to 
DIPG with reports by the Catalogue of Somatic Mutations in 
Cancer highlighting ACVR1 variants as present in only 0.3% of 
all tumor types (35). Indeed, this would seem highly suggestive 
of ACVR1 as potential oncogenic driver of tumorigenesis (18). 
However, germline mutations in ACRV1, including R206H, are 
present in patients with fibrodysplasia ossificans progressiva who 
do not proceed to develop DIPG, or other malignancies (35, 37). 
Nonetheless, as ACVR1 mutations facilitate early tumor propa-
gation in conjunction with other molecular aberrations, they 
represent novel targets for future therapies (18).
TP53 mutations, corresponding to the 17p13.1 locus, have 
been identified in 22–40% of tumor samples and frequently occur 
in the setting of PDGFR amplification (25, 27, 35). TP53 muta-
tions and allelic loss have been reported at comparable rates in 
both histone H3.3 mutation and wild-type subsets (38). TP53 and 
to a lesser extent PPM1D mutations represent obligate partners 
of H3.3 K27M that promote malignancy in DIPG (22). This 
partnership has specifically been described to evade cell death 
and senescence by possibly allowing H3.3 K27M to influence 
epigenetic regulation (22).
Recurring focal gains in receptor tyrosine kinases (RTKs) and 
regulatory cell-cycle genes in addition to phospho-mammalian 
target of rapamycin (mTOR) immunopositivity have been 
reported in DIPG and may also represent valid therapeutic targets 
(28, 29). PDGFRA is the most commonly observed amplifica-
tion, present in approximately 32% of tumors, and highlights an 
important focal gain implicated in the RTK–Ras–PI3K–Akt sign-
aling network, active in 69% of DIPG (18, 22, 27, 29). In pediatric 
gliomagenesis, PDGFRA strongly promotes phosphorylation at 
various phosphotyrosine domains, thereby initiating downstream 
signaling activation of PI3K and MAPK pathways (38). PDGFRA 
gains and amplifications co-segregate with histone H3.3 muta-
tions have an enriched proneural gene expression profile and are 
clinically aggressive regardless of histological classification (26, 
27, 39).
PIK3R1 and PIK3CA, genes involved in the PI3K pathway, 
have been recognized as oncogenes present in grade II–IV 
 gliomas including DIPG (24, 25, 39). Mutations in PIK3R1 have 
been characterized as an obligatory partner in H3.3 K27M and 
are reported in clonal populations of DIPG. Interestingly, altera-
tions in PIK3CA have been found in subclonal DIPG popula-
tions and are regarded as an accessory driver. While PIK3CA 
mutations are not crucial to DIPG development, they provide 
an important angiogenic advantage and promote cancer cell 
stemness (22). While the exact function of PIK3CA in DIPG in 
clonal and subclonal tumor evolution remains undefined, spatial 
tumor conservation of PIK3CA further supports the therapeutic 
advantage of targeting the RTK–PI3K–MAPK pathway (16).
MYC and MYCN aberrations are present in DIPG and con-
stitute transcriptional regulators that specifically enhance gene 
expression across the whole genome (18). MYCN amplification 
is associated with hypermethylation, increased histological grade, 
and chromothripsis at chromosome 2p. The aberrant functional-
ity of these transcription factors further highlights the critical 
impact of epigenetics within the DIPG mutational landscape (22). 
Additionally, G1 checkpoint regulators CCND1, 2, and 3, CDK4, 
and CDK6 have been identified as amplified in DIPG, indicating 
abnormalities in cell-cycle regulation (24).
In vivo models have highlighted anatomical and temporal asso-
ciations between neural precursor cells of the pons and DIPG cells 
(22). Upregulation of sonic hedgehog (SHh), induces hyperplasia 
of the ventral pons and may cause precursor cell populations to 
undergo tumor transformation (22, 23). However, dysregulation 
of SHh alone cannot induce oncogenesis. Homeobox and HLH 
genes are associated with brainstem tumors and have a suspected 
role in reprogramming embryonic signaling organizers during 
tumor development (27).
PReCliniCAl AnD CliniCAl 
DevelOPMenT OF TARGeTeD 
THeRAPieS FOR DiPG
Revolutionary developments in our understanding of the 
biological processes underlying DIPG have led to the establish-
ment of targeted therapeutic approaches with the aim of clinical 
translation (19–21, 35). The identification of histone mutations as 
disease-defining events has led to the investigation of epigenetic 
modifiers as potential therapies. Recently, panobinostat, an 
approved multi-histone deacetylase inhibitor, has been shown 
to have potent anti-DIPG activity (19, 40). Mechanism of action 
studies showed that panobinostat increased trimethylation and 
acetylation levels of H3K27M. Panobinostat has been shown to 
have antitumor efficacy on H3K27M expressing cells in  vitro, 
reducing both cell proliferation and viability, and potent activ-
ity in some in vivo models, but not in others (19, 40). This may 
relate to a narrow therapeutic index, with dose limiting toxicities 
seen at the concentrations required to have an antitumor effect 
(40). A phase I trial exploring the use of panobinostat as a single 
agent in DIPG is currently underway in North America (http://
ClinicalTrials.gov Identifier: NCT02717455).
GSKJ4, a H3K27 demethylase inhibitor, has also been shown 
to increase H3K27me3 in H3K27M expressing cells at inhibitory 
concentrations of 1.3–3.0 µM (20) and has demonstrated synergy 
with panobinostat (19).
An emphasis on the aberrant activation of the RTK–PI3K–
Akt pathway in DIPG has led to the investigation of therapies 
targeting this signaling network (25). In vitro use of dasatinib, 
a multi-tyrosine kinase inhibitor, has demonstrated reduced 
tumor proliferation due to the down regulation of PDGFRA 
activity and subsequent damaging of cell-cycle progression at 
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G1 (21). The use of temsirolimus, an agent which inhibits mTOR 
which is a downstream protein of PI3K (41), has been explored 
in DIPG (42). A phase I study of the concurrent administration 
of temsirolimus and perifosine, an Akt inhibitor, in pediatric 
patients with solid tumors including DIPG has tested the concept 
of dual targeting of the PI3K–Akt–mTOR pathway and shown it 
to be safe and feasible (42). Currently, an open phase I study is 
examining the use of temsirolimus with vorinostat and radiation 
therapy in patients with newly diagnosed and progressive DIPG 
(http://ClinicalTrials.gov Identifier: NCT02420613). Another 
trial has been recently opened (BIOMEDE) that is stratifying 
patients to different RTK–PI3K–mTOR pathway inhibitors 
based on expression of EGFR and/or loss of PTEN established 
following stereotactic biopsy. Patients are assigned, and in some 
case randomized to different treatment arms with erlotinib, 
dasatinib, and everolimus (http://ClinicalTrials.gov Identifier: 
NCT02233049).
The use of PD-03332991 (PD), a CDK4/6 inhibitor, has been 
explored in preclinical models of DIPG where in  vivo activ-
ity was demonstrated in combination with radiotherapy. PD 
was shown to have greater efficacy in DIPG tumor cells that 
exhibited Ink4a-ARF loss caused by cytostatic effects of halting 
progression through G0/G1 (43). Inhibition of WEE1 kinase, 
also expressed in DIPG, has been explored as a radiosensitizer 
and was demonstrated to have antitumor effects in  vitro, but 
no activity in  vivo (44). The use of temozolomide (TMZ), 
associated with MGMT inactivation and prolonged survival 
in adult GBM patients, has been investigated in DIPG patients 
but has failed to yield any therapeutic advantage (9, 10, 45, 46). 
The inefficacy of TMZ in DIPG patients may result from the 
poor association of K27M expressing tumor cells with MGMT 
methylation, present in only 3% of tissue samples (47). Thus, 
this disparity highlights the importance of biological rationale 
for driving clinical decision making (48). A recently closed 
multi-center phase II clinical study has implemented the use of 
biopsy and molecularly aided determination of treatment with 
TMZ and or erlotinib based on MGMT and EGFR status (http://
ClinicalTrials.gov Identifier: NCT01182350). The trial has 
completed recruitment with results expected after completion 
of adequate patient follow-up.
One of the challenges around the development of effective 
therapies for DIPG relates to the impermeability of the blood–
brain barrier (BBB). In fact, the BBB appears to be even more 
important in DIPG than other brain tumors, as DIPG exhibits 
reduced BBB permeability when compared to their cortical HGG 
counterparts (49). This has prompted the exploration of alterna-
tive novel delivery methods, such as the use of nanoparticles 
or distribution of chemotherapeutics via convection-enhanced 
delivery (CED) (19, 50). In the recent years, various approaches 
have been tested to improve delivery of therapies into brain 
tumors, such as, polymer/metal based nanoparticles and cell-
mediated delivery methods (51). One exciting new delivery 
method has focused on the use of bacterial cell-derived vehicles 
to transport chemotherapeutic agents across the BBB (52). These 
vehicles are conjugated with bi-specific antibodies that can recog-
nize polysaccharide moieties in the bacterial cell wall and EGFR 
moiety on the other side. Earlier studies have demonstrated by 
immunohistochemistry that DIPG express high levels of EGFR 
and reported this to be independent of gene amplification or 
mutations (28, 53). Preclinical experiments conducted in canine 
brain cancer models have shown that these EGFR-targeted vehi-
cles loaded with doxorubicin exhibited highly significant tumor 
regression (54). A phase I study (ECREST) is currently open 
using mitoxantrone loaded vehicles in patients with solid and 
CNS tumors (including DIPG) that demonstrate EGFR expres-
sion (http://ClinicalTrials.gov Identifier: NCT02687386).
Convection-enhanced delivery represents a novel therapy 
modality that allows direct administration to local anatomical 
structures in order to reduce systemic toxicity and to bypass the 
BBB (40, 50). Administration of the chemotherapeutic agent 
carmustine indicated enhanced extension of survival in an 
orthotopic animal of DIPG (55). Small clinical studies and case 
reports of CED used in DIPG patients have suggested that it is 
safe and feasible. Anderson et  al. reported on the treatment of 
two children with topotecan administered by CED. Both patients 
experienced neurological deficits following placement of bilateral 
catheters. While MRI findings exhibited a reduction in tumor 
size, the treatment was unable to prolong survival (56). Another 
study reported on a robotic navigated catheter implantation pro-
cedure to direct treatment with carboplatin. The procedure was 
well tolerated with an objective response initially seen on MRI. 
However, the patient died due to progression in regions beyond 
drug distribution (57). An additional study has been performed 
by the same research group treating a larger cohort of eight 
DIPG patients with CED of carboplatin. The investigators used 
multiple catheter implantations that were robotically directed 
and MRI guided. The patients experienced some neurological 
side effects following the first treatment but symptoms resolved 
before subsequent infusions. Preliminary results show that three 
of eight patients have survived beyond 15  months while seven 
of eight patients remained alive after a short follow-up interval 
(58). While these data suggest that the procedure is well tolerated, 
more advanced data are required to assess patient benefit. CED 
is also being employed to deliver novel therapies. For example, 
a currently open phase I trial is exploring the administration of 
a radioactively labeled antibody known as 124I-8H9 for DIPG 
patients (http://ClinicalTrials.gov Identifier: NCT01502917). 
124I-8H9 is a chimeric toxin with demonstrated specificity toward 
B7-H3, a membrane protein that has been recognized as tumor 
selective in DIPG (50, 59). Conjugation of 124I to the anchoring 
antibody will allow the therapeutic effects of the radionucleotide 
against glioma cells to extend beyond B7-H3 tumor expressing 
cells (59). While the feasibility of CED has been established, 
ongoing studies are helping to improve the instrumentation to 
determine optimal flow levels and maximize safety and efficacy 
(50, 56).
The failure of conventional cytotoxic therapies in DIPG has 
prompted the exploration of alternative therapeutic strategies, 
such as immunotherapies, that target glioma-associated anti-
gens (GAAs), which are preferentially expressed by tumor cells 
(60,  61). Immunohistochemical (IHC) evaluation of IL-13Rα2, 
EphA2, and survivin proteins, three GAAs previously recognized 
in adult gliomas, has demonstrated expression of at least one GAA 
in 87% of DIPG samples (60). A small phase I trial evaluating 
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subcutaneous administration of IL-13Rα2, EphA2, and survivin 
peptide-based vaccinations was well tolerated with preliminary 
indications of immunologic activity and clinical response (61). 
The targeting of multiple GAAs is therapeutically advantageous 
to overcome mixed GAA expression patterns among tumor sam-
ples and combat possible immunoediting that may occur within 
subclonal populations (60, 61). An additional phase I trial is cur-
rently exploring the delivery of IL13-PE38QQR, a recombinant 
mutated Pseudomonas aeruginosa toxin, via CED for pediatric 
patients with DIPG and HGG (50, 62). The presence of IL-13Rα2 
alone has been recognized in 61–67% of DIPG tumors and is 
virtually non-detectable in normal brain tissue, therefore mak-
ing it a suitable candidate for targeted immunotherapy (60, 62). 
Future trials will likely require pretreatment biopsies to identify 
biomarkers by IHC in order to appropriately stratify patients 
based on the expression of GAAs (62).
COnClUSiOn
The lack of progress of over three decades of clinical trials means 
that DIPG remains an almost universally fatal pediatric tumor. 
Improved access to tumor samples for preclinical investigations 
has led to substantial breakthroughs and the identification of 
important genomic mutations responsible for tumorigenesis. 
Moreover, the significant progress toward uncovering targetable 
mutations has already vastly transformed the preclinical and 
clinical landscape. Further elucidation of the pathways involved 
in the growth and development of DIPG will improve our under-
standing of the biological landscape and by extension provide 
rationales for novel treatment protocols.
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